Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined the dissociation rates of these INIs with integrase (IN)-DNA complexes containing a broad panel of IN proteins, including IN substitutions corresponding to signature RAL and ELV resistance mutations. DTG dissociates slowly from a wild-type IN-DNA complex at 37°C with an off-rate of 2.7 × 10 −6 s −1 and a dissociative half-life ( t 1/2 ) of 71 h, significantly longer than the half-lives for RAL (8.8 h) and ELV (2.7 h). Prolonged binding ( t 1/2 , at least 5 h) was observed for DTG with IN-DNA complexes containing E92, Y143, Q148, and N155 substitutions. The addition of a second substitution to either Q148 or N155 typically resulted in an increase in the off-rate compared to that with the single substitution. For all of the IN substitutions tested, the off-rate of DTG from IN-DNA complexes was significantly slower (from 5 to 40 times slower) than the off-rate of RAL or ELV. These data are consistent with the potential for DTG to have a higher genetic barrier to resistance, provide evidence that the INI off-rate may be an important component of the mechanism of INI resistance, and suggest that the slow dissociation of DTG may contribute to its distinctive resistance profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the dissociation half-times of dolutegravir and bictegravir from the wild-type HIV-1 intasome were reported to be ~100 and 160 h, respectively164,165.”
From Structure and function of retroviral integrase (2022) · cites this paper as [164]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complete nucleotide sequence of the AIDS virus, HTLV-III
Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B., Josephs, S. F., Doran, E. R., Rafalski, J. A., Whitehorn, E. A., Baumeister, K., et al. (1985) · Nature · doi:10.1038/313277a0 · Cited by 2,245 · cited 1×
“to make mutations in the wild type HIV-1 BH10 IN sequence (41).”
BackgroundDrug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“Since INI binding generates nonreplicative forms of unintegrated viral cDNA, such as 2 long terminal repeats (27), there is less opportunity for the virus to undergo further rounds of replication which can generate additional mutations and thereby VOL.”
BackgroundRaltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691 · cited 1×
“21, 30, 40, 43, 47) and in clinical studies (5, 35, 36, 45).”
Retroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509 · cited 2×
“For RAL, two main pathways for resistance involve signature mutations which are initially observed at amino acids Q148 and N155 and are almost invariably found with secondary mutations which may increase resistance and impact viral fitness and catalytic efficiency (5, 11, 18, 38, 40).”
BackgroundMarkowitz, M., Nguyen, B.-Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R. D., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318157131c · Cited by 408 · cited 1×
“21, 30, 40, 43, 47) and in clinical studies (5, 35, 36, 45).”
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Self-citationShimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01534-07 · Cited by 343
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., & Cherepanov, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010246107 · Cited by 305 · cited 1×
“The crystal structures of prototype foamy virus (PFV) IN in complex with DNA and RAL, ELV, (24), or DTG (25) and HIV-1 IN structural modeling studies (8, 9) provide insight into INI binding modes and how substitutions in the active site could impact INI binding.”
Background
Research works printed but not linked: 9
- 8. DeAnda F., Hattori K., Yoshinaga T., Kawasuji T., Underwood M. R. 2010. Structural models of HIV-1 integrase and DNA in complex with S/GSK1349572, raltegravir, or elvitegravir: structure-based rationale for INI resistance profiles. Antiviral Ther. 15(Suppl. 2):A73 [Google Scholar]
- 9. DeAnda F., et al. 2010. Structural rationale for slow S/GSK1349572 dissociation from wild type (WT) and raltegravir (RAL) resistant HIV-1 integrase (IN), abstr. H-1166. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother American Society for Microbiology, Washington, DC [Google Scholar]
- 10. DeJesus E., et al. 2007. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137), abstr. TUPEB032. Abstr. 4th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention International AIDS Society, Geneva, Switzerland [Google Scholar]
- 13. Dicker I. B., et al. 2011. Longer integrase inhibitor dissociation half-lives induce persistent anti-HIV effects in cell culture, abstr. 521. Abstr. 18th Conf. Retrovir. Opportunistic Infect [Google Scholar]
- 23. Grobler J. A., et al. 2009. Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitors, abstr. O-10. Abstr. 10th Int. Workshop Clin. Pharmacol. HIV Ther. [Google Scholar]
- 28. Hluhanich R., et al. 2010. HIV integrase inhibitors (INIs) do not exert a post-antibiotic effect (PAE) despite slow dissociation from IN-DNA complexes in vitro, abstr. H-930. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother American Society for Microbiology, Washington, DC [Google Scholar]
- 29. Johns B., et al. 2010. The discovery of S/GSK1349572: a once-daily next generation integrase inhibitor with a superior resistance profile, abstr. 55. Abstr. 17th Conf. Retrovir. Opportunistic Infect. [Google Scholar]
- 46. Underwood M. R., Johns B., Sato A., Fujiwara T., Spreen W. 2009. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy, abstr. WEPEA098. Abstr. 5th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention International AIDS Society, Geneva, Switzerland [Google Scholar]
- 48. Yoshinaga T., Kanamori-Koyama M., Seki T., Sato A., Fujiwara T. 2010. Strong inhibition of wild-type and integrase inhibitor (INI)-resistant HIV integrase (IN) strand transfer reaction by the novel INI S/GSK1349572. Antivir. Ther. 15(Suppl. 2):A12 [Google Scholar] Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)
Cited by
Items 101–200 of 258
Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance
Hachiya, A., Ode, H., Matsuda, M., Kito, Y., Shigemi, U., Matsuoka, K., Imamura, J., Yokomaku, Y., Iwatani, Y., & Sugiura, W. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.04.014 · Cited by 25
Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
Richetta, C., Tu, N. Q., & Delelis, O. (2022) · Viruses · doi:10.3390/v14122591 · Cited by 24
Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance
Malet, I., Thierry, E., Wirden, M., Lebourgeois, S., Subra, F., Katlama, C., Deprez, E., Cálvez, V., Marcelin, A., & Delelis, O. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv197 · Cited by 24
Hachiya, A., Kirby, K. A., Ido, Y., Shigemi, U., Matsuda, M., Okazaki, R., Imamura, J., Sarafianos, S. G., Yokomaku, Y., & Iwatani, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00315-17 · Cited by 24
“In contrast to the first-generation INSTIs, DTG seems to adapt its position and conformation to the altered geometry of the active site of N224H mutant.”
BackgroundInfluentialSaladini, F., Meini, G., Bianco, C., Monno, L., Punzi, G., Pecorari, M., Borghi, V., Pietro, M. D., Filice, G., Gismondo, M. R., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03917.x · Cited by 23
“it Dolutegravir (DTG, formerly S/GSK1349572) is a next-generation HIV-1 and HIV-2 integrase inhibitor (INI) with an apparently increased genetic barrier to resistance with respect to first-generation INIs such as raltegravir (RTG) [1,2].”
BackgroundMalet, I., Delelis, O., Nguyen, T., Leducq, V., Abdi, B., Morand‐Joubert, L., Cálvez, V., & Marcelin, A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz377 · Cited by 23
Multifunctional facets of retrovirus integrase
Grandgenett, D. P., Pandey, K. K., Bera, S., & Aihara, H. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i3.83 · Cited by 23
Capetti, A. F., Sterrantino, G., Cossu, M. V., Cenderello, G., Cattelan, A. M., Socio, G. V. D., Rusconi, S., Riccardi, N., Baldin, G., Cima, S., et al. (2016) · Antiviral Therapy · doi:10.3851/imp3095 · Cited by 22
“The positive response to simplification and to rescue with the dual combination of DTG plus DRV/r mainly reflects the pharmacodynamic properties [12,16] and the high genetic barrier of both drugs [10,11].”
BackgroundRetroviral integrase: Structure, mechanism, and inhibition
Passos, D. O., Li, M., Craigie, R., & Lyumkis, D. (2021) · The Enzymes · doi:10.1016/bs.enz.2021.06.007 · Cited by 23
“It was later clarified that one reason for their efficacy is the very long dissociative half-life of the drug from the nucleoprotein assembly [150,151].”
BackgroundEvaluation of the impact of multivalent metal ions on the permeation behavior of Dolutegravir sodium
Grießinger, J. A., Hauptstein, S., Laffleur, F., Netsomboon, K., & Bernkop‐Schnürch, A. (2015) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2015.1115869 · Cited by 22
HIV–1 resistance to dolutegravir: update and new insights
Wainberg, M. A., & Han, Y.-S. (2015) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)31150-x · Cited by 22
“Generally, it is accepted that DTG is effective against many RAL- and EVG-resistant variants because binding of DTG to integrase–DNA complexes is much longer than that of either RAL or EVG [4,12,16,19].”
BackgroundPathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance
Malet, I., Ambrosio, F. A., Subra, F., Herrmann, B., Leh, H., Bouger, M.-C., Artese, A., Katlama, C., Talarico, C., Romeo, I., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx529 · Cited by 21
Marcelin, A., Grudé, M., Charpentier, C., Bellecave, P., Guen, L. L., Pallier, C., Raymond, S., Mirand, A., Bocket, L., Fofana, D., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz021 · Cited by 21
Candidates for inclusion in a universal antiretroviral regimen
Cahn, P. E. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000388 · Cited by 19
Brown, A. N., Adams, J. R., Baluya, D. L., & Drusano, G. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00469-15 · Cited by 19
Heredia, A., Hassounah, S. A., Medina-Moreno, S., Zapata, J. C., Le, N. M., Han, Y.-S., Foulke, J. S., Davis, C., Bryant, J., Redfield, R., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx195 · Cited by 18
Ren, T., Zhu, X., Jusko, N. M., Krzyżański, W., & Jusko, W. J. (2022) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-022-09822-y · Cited by 18
“Several drugs demonstrated extremely long dissociation halflives, such as darunavir (247 h) and dolutegravir (71 h), which explains their potent activities [16, 17].”
BackgroundWainberg, M. A. (2012) · Scientifica · doi:10.6064/2012/238278 · Cited by 18
Bollen, P., Reiss, P., Schapiro, J., & Burger, D. M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1059818 · Cited by 17
“This is a result of a number of favorable attributes including: i) small reductions in susceptibility from individual integrase mutations [11,45]; ii) slow dissociation rate from the integrase--DNA complex [43]; and iii) trough concentrations substantially above the protein adjusted IC90 for single mutations [16-18].”
BackgroundGriesel, R., Hill, A. M., Meintjes, G., & Maartens, G. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16473.1 · Cited by 17
Newly approved integrase inhibitors for clinical treatment of AIDS
Gu, W.-G. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.09.013 · Cited by 17
Nance, R. M., Vannappagari, V. X., Smith, K. Y., Johannes, C. B., Calingaert, B., Saltus, C. W., Mayer, K. H., Whitney, B. M., Rodriguez, B. A., Moore, R. D., et al. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002075 · Cited by 17
“Switched regimen (all changes), N (%) 66 (15) 93 (12) 13 (16) 0.”
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK
Merlini, E., Federico, C., Casabianca, A., Orlandi, C., Ancona, G., Cogliandro, V., Tincati, C., Bini, T., MAGNANI, M., Monforte, A. D., et al. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.8.21487 · Cited by 17
Métifiot, M., Johnson, B. C., Kiselev, E., Marler, L., Zhao, X. Z., Burke, T. R., Marchand, C., Hughes, S. H., & Pommier, Y. G. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw592 · Cited by 16
“Here, we performed biochemical experiments and molecular modeling with the WT and the double-mutant (G140S-Q148H [SH]) that causes significant resistance to RAL and EVG and to a lesser extent to DTG (2,11,12,22,26).”
InfluentialBangalee, A., Hanley, S., & Bangalee, V. (2022) · South African Medical Journal · doi:10.7196/samj.2022.v112i10.16596 · Cited by 16
Dolutegravir: A New HIV Integrase Inhibitor for the Treatment of HIV Infection
Max, B. E., & Vibhakar, S. (2014) · Future Virology · doi:10.2217/fvl.14.80 · Cited by 16
Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance
Dewdney, T. G., Wang, Y., Kovari, I. A., Reiter, S. J., & Kovari, L. C. (2013) · Journal of Structural Biology · doi:10.1016/j.jsb.2013.07.008 · Cited by 16
Current models of care for the management of HIV patients with comorbidities in England: a survey
Cooper, V., & Nixon, E. (2016) · Sussex Research Online (University of Sussex) · Cited by 15
Kengo, A., Nabisere, R. M., Gausi, K., Musaazi, J., Buzibye, A., Omali, D., Aarnoutse, R. E., Lamorde, M., Dooley, K. E., Sloan, D. J., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00430-23 · Cited by 15
“Moreover, dolutegravir has a long dissociative half-life from viral integrase of about 71 hours (3), which may provide protection against drug concentrations temporarily falling below the PA-IC 90 .”
BackgroundMarcelin, A., Charpentier, C., Bellecave, P., Abdi, B., Chaix, M., Ferré, V., Raymond, S., Fofana, D., Bocket, L., Mirand, A., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab193 · Cited by 15
Dolutegravir for the treatment of adult patients with HIV-1 infection
Wu, G. D., Abraham, T., & Saad, N. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.907525 · Cited by 15
“This occurs via two critical steps mediated by integrase: 3 ́ processing, which is due to removal of two nucleotides from each end of viral DNA by integrase, and strand transfer, whereupon insertion of two 3 ́ viral DNA ends into opposite strands of host DNA occurs [13].”
BackgroundInfluentialRaltegravir in HIV-1 Infection: Safety and Efficacy in Treatment-Naïve Patients
Pandey, K. K. (2011) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s5022 · Cited by 14
Dolutegravir: an exciting new kid on the block
Blanco, J. L., & Whitlock, G. G. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.868883 · Cited by 14
“With regard to resistance, data to date show that DTG possesses a resistance profile distinct from that of the first-generation INIs, retaining substantial activity against viruses harboring two of the three main pathways of resistance selected after virological failure to the first-generation INIs, Y143 and N155H, an…”
BackgroundAndreoni, M., Marcotullio, S., Puro, V., Carli, G. D., Tambussi, G., Nozza, S., Gori, A., Rusconi, S., Santoro, M. M., Clementi, M., et al. (2015) · PubMed · Cited by 13
Oliveira, M., Mésplède, T., Moisi, D. D., Ibanescu, R.-I., BRENNER, B. G., & Wainberg, M. A. (2015) · AIDS · doi:10.1097/qad.0000000000000866 · Cited by 13
“In addition, DTG has a longer dissociative half-life from the integrase protein than either RAL or EVG, both in biochemical and in cell-based assays [25,26].”
BackgroundEvaluation of dolutegravir safety for the treatment of HIV-1
Keeshin, S. W., & Feinberg, J. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.973845 · Cited by 13
“This may be due to its considerably slower dissociation rate -- 5- to 40-fold -- from the integrase-DNA complex in viruses that contain the N155, Q148 or Y143 mutations [15].”
BackgroundPharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers
Elliot, E. R., Cerrone, M., Challenger, E., Else, L., Amara, A., Bisdomini, E., Khoo, S., Owen, A., & Boffito, M. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky384 · Cited by 13
Calcagno, A., D’Avolio, A., & Bonora, S. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1056732 · Cited by 13
“For all of the integrase substitutions tested, the off-rate of dolutegravir from integrase-DNA complexes was significantly slower (from 5 -- 40 times slower) than the off-rate of raltegravir or elvitegravir [36].”
Inhibitors of HIV-1 Entry and Integration: Recent Developments and Impact on Treatment
Sharma, A. K., George, V., Valiathan, R., Pilakka‐Kanthikeel, S., & Pallikkuth, S. (2013) · Recent Patents on Inflammation & Allergy Drug Discovery · doi:10.2174/1872213x11307020006 · Cited by 12
“Other studies have suggested its longer half life and prolonged binding to integraseDNA complex as a reason for this [102].”
BackgroundCutillas, V., Mésplède, T., Anstett, K., Hassounah, S. A., & Wainberg, M. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04274-14 · Cited by 12
Role of Raltegravir in HIV-1 Management
Rokas, K. E. E., Bookstaver, P. B., Shamroe, C. L., Sutton, S. S., Millisor, V. E., Bryant, J. E., & Weissman, S. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q616 · Cited by 12
Casado, J. L., Monsalvo, M., Rojo, A., Fontecha, M. B., & Rodríguez-Sagrado, M. Á. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1478726 · Cited by 12
CYP1A1 and 1B1-mediated metabolic pathways of dolutegravir, an HIV integrase inhibitor
Zhu, J., Wang, P., Li, F., Lu, J. L., Shehu, A. I., Xie, W., McMahon, D. K., & Ma, X. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.012 · Cited by 12
The clinical pharmacology of integrase inhibitors
Perri, G. D., Calcagno, A., Trentalange, A., & Bonora, S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1553615 · Cited by 11
“DTG was associated to a dissociation time of 71 instead of 16 h in case of WT virus), the gap between the two INSTIs generation persists [44].”
BackgroundDolutegravir plus lamivudine for the treatment of HIV-1 infection
Ciccullo, A., Baldin, G., Borghetti, A., & Giambenedetto, S. D. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1729742 · Cited by 11
Santevecchi, B. A., Miller, S., & Childs‐Kean, L. M. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020933772 · Cited by 11
The crosstalk between antiretrovirals pharmacology and HIV drug resistance
Giacomelli, A., Pezzati, L., & Rusconi, S. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1782737 · Cited by 11
“The R263 K mutation, observed in vitro and in vivo in INSTI-naïve patients failing DTG-containing regimen in the SAILING study, confers crossresistance to DTG, EVG, and RAL [170,171].”
BackgroundInfluentialXue, W., Zhu, F., Yang, F., Yang, J., Zhang, Z., Tu, G., & Yao, X. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210708090123 · Cited by 11
An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV
Christensen, B. L., & Tan, D. H. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2029409 · Cited by 11
Integrase inhibitors: current protagonists in antiretroviral therapy
Loaiza, J. D., Chvatal‐Medina, M., Hernández, J. C., & Rugeles, M. T. (2023) · Immunotherapy · doi:10.2217/imt-2023-0011 · Cited by 11
Veselinović, M., Yang, K.-H., Sykes, C., Remling‐Mulder, L., Kashuba, A. D. M., & Akkina, R. (2016) · Virology · doi:10.1016/j.virol.2015.12.014 · Cited by 11
“Moreover, the binding of RAL to the HIV-1 pre-integration complex (PIC) is considered to be irreversible thus having a durable anti-viral effect (Grobler et al., 2009; Hightower et al., 2011).”
BackgroundABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics
Zhu, J., Tian, X., Shehu, A. I., McMahon, D. K., & Ma, X. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.264424 · Cited by 11
“DTG overcomes HIV drug resistance to the first generation of integrase inhibitors (Hightower et al., 2011;Eron et al., 2013).”
BackgroundDepatureaux, A., Quashie, P. K., Mésplède, T., Han, Y.-S., Koubi, H., Plantier, J., Oliveira, M., Moisi, D. D., BRENNER, B. G., & Wainberg, M. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03819-14 · Cited by 11
“INSTIs represent a new drug class among ARVs (25, 26) and include raltegravir (RAL), elvitegravir (EVG), and DTG.”
BackgroundInfluentialCattaneo, D., Rizzardini, G., & Gervasoni, C. (2017) · AIDS · doi:10.1097/qad.0000000000001394 · Cited by 11
“Additionally, it should be also considered that dolutegravir exhibits significantly slower dissociation than raltegravir and elvitegravir from integrase–DNA complexes [13].”
BackgroundWeld, E. D., Beattie, T., Moodley, J., Mapendere, M., Salles, I., Solans, B. P., Nonyane, B. A. S., Wiesner, L., Nielson, T., Edward, V., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00002-5 · Cited by 10
Dolutegravir inhibits HIV-1 Env evolution in primary human cells
Mésplède, T., Moisi, D. D., Oliveira, M., Ibanescu, I., Ohnona, F., BRENNER, B. G., & Wainberg, M. A. (2015) · AIDS · doi:10.1097/qad.0000000000000606 · Cited by 10
“These observations are consistent with studies that showed that DTG can bind to the integrase protein with a dissociative half-life that is superior to those of both RAL and EVG [29].”
BackgroundInfluentialElvitegravir concentrations in seminal plasma in HIV ‐1‐infected men
Imaz, A., Niubó, J., Kashuba, A. D. M., Ferrer, E., Sykes, C., Rozas, N., Acerete, L., Vila, A., & Podzamczer, D. (2016) · HIV Medicine · doi:10.1111/hiv.12417 · Cited by 10
Osman, N., Mésplède, T., Quashie, P. K., Oliveira, M., Zanichelli, V., & Wainberg, M. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv176 · Cited by 10
Cheng, X., Gao, P., Sun, L., Tian, Y. E., Zhan, P., & Liu, X. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1360283 · Cited by 10
Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection
Hester, E. K., & Astle, K. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019831674 · Cited by 10
HIV-1 Integrase Resistance among Highly Antiretroviral Experienced Patients from Morocco
Alaoui, N., Alaoui, M. A. E., Annaz, H. E., Farissi, F. Z., Alaoui, A. S., Fahime, E. E., & Mrani, S. (2019) · Intervirology · doi:10.1159/000501016 · Cited by 9
Dumitrescu, T. P., Peddiraju, K., Fu, C., Bakshi, K. K., Yu, S., Zhang, Z., Tenorio, A. R., Spancake, C., Joshi, S., Wolstenholme, A., et al. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.740 · Cited by 9
Mikasi, S. G., Isaacs, D., Chitongo, R., Ikomey, G. M., Jacobs, G. B., & Cloete, R. E. A. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06059-x · Cited by 9
“In addition, DTG is purported to be able to readjust its position and conformation in response to structural changes in the active sites of EVG- or RAL resistant IN enzymes and avoid some cross-resistance due to slower dissociation (24, 34).”
BackgroundHIV-1 Integrase Drug Discovery Comes of Age
Demeulemeester, J., Maeyer, M. D., & Debyser, Z. (2013) · Topics in medicinal chemistry · doi:10.1007/7355_2013_33 · Cited by 9
Pandey, K. K., Bera, S., Korolev, S., Campbell, M. A., Yin, Z., Aihara, H., & Grandgenett, D. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.573311 · Cited by 9
“The slow-dissociating MK-2048, MK-0536, and DTG inhibitors in comparison with RAL for HIV IN-DNA complexes (24, 26) appear to possess key properties in producing a highly stabilized RSV SC, although RAL is 70% as effective as the slow-dissociating STIs (Fig.”
BackgroundCovington, N., Luetkemeyer, A. F., Imperial, M. Z., Dawson, R., Cramer, Y. S., Rosenkranz, S., Swindells, S., Gelmanova, I. Y., Avihingsanon, A., Arduino, R. C., et al. (2025) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000562 · Cited by 8
Brief Histories of Retroviral Integration Research and Associated International Conferences
Grandgenett, D. P., & Engelman, A. (2024) · Viruses · doi:10.3390/v16040604 · Cited by 8
“[161,162].”
Guan- Nan, L. I. U. (2014) · Medicinal Chemistry · doi:10.4172/2161-0444.1000196 · Cited by 8
New Antiretroviral Therapies and Potential Drug Interactions in HIVInfected Drug Abusers
Cory, P. R. T. (2014) · Journal of Antivirals & Antiretrovirals · doi:10.4172/jaa.10000103 · Cited by 8
“Moreover, owing to both the slower dissociation rate from binding pocket of integrase enzyme and its ability to undergo conformational changes in mutated active site of the viral enzyme, dolutegravir has been demonstrated to have a higher threshold for development of viral resistance [38,39].”
BackgroundSafakish, M., Hajimahdi, Z., Vahabpour, R., Zabihollahi, R., & Zarghi, A. (2019) · Medicinal Chemistry · doi:10.2174/1573406415666190826161123 · Cited by 8
Musat, M., Nițulescu, G. M., Surleac, M. D., Tsatsakis, A. M., Spandidos, D. A., & Margina, D. M. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10777 · Cited by 8
New designs for HIV-1 integrase inhibitors: a patent review (2018-present)
Taoda, Y., Sugiyama, S., & Seki, T. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2178300 · Cited by 7
Self-citationHIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity
Anstett, K., BRENNER, B. G., Mésplède, T., & Wainberg, M. A. (2017) · Journal of Virology · doi:10.1128/jvi.00912-17 · Cited by 7
“IN affected the inhibitor dissociation rate from the IN-DNA complex (36).”
BackgroundRaltegravir flexibility and its impact on recognition by the HIV‐1 IN targets
Arora, R., de Beauchêne, I. C., Polański, J., Laine, É., & Tchertanov, L. (2013) · Journal of Molecular Recognition · doi:10.1002/jmr.2277 · Cited by 7
“…(IC50 values) in cellular antiviral and recombinant enzyme assays, kinetic analysis and slow-binding inhibition of IN-catalyzed ST reaction (Hazuda et al., 2000; Grobler et al., 2002; Copeland et al., 2006; Markowitz et al., 2006; Dicker et al., 2008; Garvey et al., 2009; Hightower et al., 2011).”
BackgroundEficacia de dolutegravir en pacientes experimentados: estudios SAILING y VIKING
Moreno, S., & Berenguer, J. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(15)30006-9 · Cited by 7
“Puntuación fenotípica = 2 181/250 (72%) 169/267 (63%) 9,1% (1,1-17,1)”
Punyawudho, B., Chanruang, A., Ueaphongsukkit, T., Gatechompol, S., Ubolyam, S., Cho, Y., Shin, J., & Avihingsanon, A. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13244 · Cited by 6
“A potential explanation could be due to a slower dissociation of DTG from a wild-type integrase-DNA complexes, with a half-life of 71 h. 27 Thus, viral suppression is still present, despite having transient DTG concentrations below the in vitro targeted level.”
Naidoo, A., Waalewijn, H., Naidoo, K., Letsoalo, M. P., Cromhout, G., Sewnarain, L., Mosia, N. R., Osuala, E. C., Wiesner, L., Wasmann, R. E., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(24)00312-6 · Cited by 6
Rashid, I., Unger, N. R., Willis, C., Dhippayom, T., Ramgopal, M. N., Sherman, E. M., Yared, N. F., Safran, R., Swiatlo, E., Weinberg, A. R., et al. (2025) · HIV Medicine · doi:10.1111/hiv.70050 · Cited by 6
Dolutegravir once daily with rifampicin for HIV and tuberculosis
Naidoo, A., & Dooley, K. E. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00115-7 · Cited by 6
New Antiretrovirals for HIV and Antivirals for HBV
Lazerwith, S. E., Siegel, D. S., McFadden, R. M., Mish, M., & Tse, W. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12407-2 · Cited by 6
Repurposing FDA-approved drugs as HIV-1 integrase inhibitors: an in silico investigation
Ha, C. H. X., Lee, N. K., Rahman, T., Hwang, S. S., Yam, W. K., & Wezen, X. C. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2028677 · Cited by 6
“We posit that being able to simulate INSTIs in a longer biological time is important as the residence time of INSTIs impacts the drug efficacy in vivo (Hightower et al., 2011).”
BackgroundCada, D. J., Levien, T. L., & Baker, D. E. (2014) · Hospital Pharmacy · doi:10.1310/hpj4902-184 · Cited by 6
Dolutegravir-associated hyperglycemia: a narrative review
Buzibye, A., Castelnuovo, B., Bollinger, R. C., Ssebulime, J., Omali, D., Muller, D., Mulindwa, F., Laker, E. A. O., Waitt, C. J., Andia, I., et al. (2025) · AIDS Research and Therapy · doi:10.1186/s12981-025-00800-1 · Cited by 5
“Dolutegravir inhibits HIV integrase by chelating magnesium at the enzyme’s catalytic core site [41].”
Quashie, P. K., Mésplède, T., Han, Y.-S., Veres, T., Osman, N., Hassounah, S. A., Sloan, R. D., Xu, H.-T., & Wainberg, M. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02916-14 · Cited by 5
The HIV-1 Integrase: Modeling and Beyond
Arora, R., & Tchertanov, L. (2013) · InTech eBooks · doi:10.5772/52344 · Cited by 5
Thierry, E., Lebourgeois, S., Simon, F., Delelis, O., & Deprez, E. (2017) · Scientific Reports · doi:10.1038/s41598-017-14564-w · Cited by 5
Arora, R. (2012) · theses.fr (ABES) · doi:10.70675/cbc4f806z2bc2z4443za965z5841ac216291 · Cited by 5
Kalata, N. L., Bello, G., Pals, S. L., Kabaghe, A. N., Mkungudza, J., Bighignoli, B., Panja, L., Bilaal, W., Kusakale, G., Chitenje, M., et al. (2025) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003744 · Cited by 4
Oligomerization of Retrovirus Integrases
Grandgenett, D. P., & Aihara, H. (2018) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-10-8456-0_10 · Cited by 4
Bases moleculares dos compostos antirretrovirais: um enfoque nos inibidores de transcriptase reversa
de Siqueira, E. C., de França, J. A. A., Doboszewski, B. D., de Siqueira, E. C., de França, J. A. A., & Doboszewski, B. D. (2026) · doi:10.66697/49dvh088 · Cited by 3
Maseke, I. A., Joachim, A., Kamori, D., Abade, A., Moremi, N., & Majigo, M. V. (2024) · HIV Research & Clinical Practice · doi:10.1080/25787489.2024.2400827 · Cited by 3
“Studies have shown varying prevalence of HIV drug resistance (HIVDR); about 9% among ART naïve youth and 90% among children and adolescents [13, 14].”
HIV Resistance to Dolutegravir Varies With Coadministered Agents
Beck, I. A., Boyce, C. L., Bishop, M. D., Oldroyd, A., du Toit, L. D. V., Saimen, A., Ramarope, K. M., Hitchcock, S., du Plessis, N., Mbogo, L., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf481 · Cited by 3
Singh, R. P., Shaik, J. S., Skoura, N., Joshi, S., Shreeves, T., Casillas, L., & Buchanan, A. M. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001859 · Cited by 3
Ciubotaru, M., Musat, M. G., Surleac, M. D., Ionita, E., Petrescu, A., Abele, E., & Abele, R. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666180406114405 · Cited by 3
Osman, N., Mésplède, T., Oliveira, M., Hassounah, S. A., Wainberg, M. A., & BRENNER, B. G. (2018) · AIDS · doi:10.1097/qad.0000000000001903 · Cited by 3
Desarrollo de darunavir en todo el espectro de la infección por el VIH
Llibre, J. M. (2018) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(18)30391-4 · Cited by 3
Khoury, L. E., Hage, K. E., Piquemal, J., Fermandjian, S., Maroun, R. G., Gresh, N., & Hobaika, Z. (2019) · PeerJ Physical Chemistry · doi:10.7717/peerj-pchem.6 · Cited by 3
Capetti, A. F., Sterrantino, G., Cossu, M. V., Cenderello, G., Cattelan, A. M., Socio, G. V. D., Rusconi, S., Riccardi, N., Baldin, G., Cima, S., et al. (2016) · Antiviral Therapy · doi:10.3851/imp3109 · Cited by 3
Impact of Latent Reservoirs, Latent Infection Delays, and Treatments on HIV Dynamics
Alalhareth, F. K., Albishri, M. I., Alharbi, M. H., & Hajji, M. E. (2026) · Mathematics · doi:10.3390/math14101675 · Cited by 2
Dolutégravir : un nouvel inhibiteur de l’intégrase dans l’arsenal thérapeutique anti-VIH
Ghosn, J. (2015) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2015.07.001 · Cited by 2
Metadata
- Authors
- Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., Seki, T., Kobayashi, M., & Underwood, M. R.
- Affiliations
- GlaxoSmithKline, Research Triangle Park, North Carolina
- Shionogi (Japan) (JP)
- Corresponding author
- Underwood, Mark R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-10
- Volume
- 55
- Issue
- 10
- Pages
- 4552-4559
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3187001
- OpenAlex
- W2144255757
- Cited by
- 226
- References
- 39
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 13 · 2020: 9 · 2019: 16 · 2018: 11 · 2017: 19 · 2016: 16 · 2015: 32 · 2014: 27 · 2013: 23 · 2012: 17
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- dolutegravir, raltegravir, elvitegravir, HIV-1 integrase inhibitors, integrase inhibitor resistance, integrase-DNA complex, dissociation rate, dissociation rate constant, resistance mutations, resistance mechanisms
- MeSH terms
- Raltegravir Potassium, Dolutegravir, DNA, Viral, Genotype, Heterocyclic Compounds, 3-Ring, Mutation, Oxazines, Piperazines, Pyridones, Pyrrolidinones, Quinolones, HIV-1, DNA, Complementary, HIV Integrase, HIV Integrase Inhibitors, Amino Acid Substitution, Drug Resistance, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.